People & Management

Kashiv has over 100 employees, including 42 Ph.D. scientists, with extensive pre-formulation, analytical, formulation, drug development, regulatory approval, and commercialization experience from a variety of major research-based pharmaceutical, biotechnology, and drug delivery companies.

The scientific management team has inventorship of over 40 issued patents, and a significant number of peer-reviewed scientific publications. These key scientists and leaders have been recipients of numerous awards for the invention of advanced drug delivery systems during their careers and are well known in the pharmaceutical world for their contributions. Read more about the core leadership team below.

Leadership

Navnit H. Shah, PhD – President and CSO

With almost 40 years of Formulation R&D experience in various novel drug delivery platforms, Dr. Shah has received numerous awards for his distinguished contributions to the biomedical industry, such as the Thomas Alva Edison Award for excellence in Innovation, Creativity and Ingenuity (2005), the New Jersey Association for Biomedical Research Leadership Award (2010) and New Jersey Inventor of the Year (2011). Dr. Shah has been named as the inventor or co-inventor of 20 issued patents and 30 patent applications in progress, primarily in the area of drug delivery, and has published over 90 publications. Prior to joining Kashiv, he was Distinguished Scientist and Head of the Oral Dosage Form Development Group at Hoffmann-La Roche. Dr. Shah also had the privilege of serving as an Adjunct Professor at the University of Rhode Island.

Pavan Handa, MBA – EVP and Chief Business Officer

PavanHSMr. Handa has held senior management positions in business development, strategy, and venture management at some of the leading specialty pharmaceutical, drug delivery, and life sciences companies. In his most recent positions, as Senior Vice President of Business Development at Antares Pharma, and previously as Vice President of Business Development & Alliances at Noven Pharmaceuticals, he diversified the product, revenue, and strategic partnership base, significantly increasing the market valuation of both companies. During the past twenty five years, he has completed over 50 deals that have generated billions of dollars worth of value in the biopharmaceutical industry through strategic partnering, licensing, acquisitions, divestitures, and commercialization of new products and business ventures.

Wantanee Phuapradit, PhD – EVP, Research & Development

Wantanee Phuapradit, PhDDr. Phuapradit has more than 25 years of formulation R&D experience, predominantly in the areas of solubility enhancement, modified release technology and differentiated complex dosage form development. She is a co-inventor of 12 drug delivery patents and has held senior positions at Roche and Barr/Teva.

 

Martin H. Infeld, PhD – EVP, Business Development Contract Services

Martin Infeld, PhDDr. Infeld has more than thirty-eight years experience in the development of formulations and drug delivery systems. He has been a co-inventor of numerous patents and a co-author of many papers in the area of formulation and drug delivery. Prior to joining Kashiv, he was a Research Director at Hoffmann-La Roche, where he was responsible for the formulation development and clinical manufacture of sterile and non-sterile dosage forms and a key member of numerous project and management teams.

Mankit Ho, PhD – SVP, Research & Development

Dr. Ho has more than thirteen years of experience in analytical method development of complex oral drug delivery systems, including reverse engineering. He is also the co-inventor of novel analytical technique patents and held senior positions at Barr/Teva.

 

Duk Soon Choi, PhD – VP, Preformulation and Chemistry

Duk Soon Choi, PhDOver the past 25 years, Dr. Choi has distinguished himself as a premier chemist in the field of drug discovery and development. His expertise includes clinical candidate selection, prodrug design, salt/polymorph screening, material property characterization and amorphous formulation development. Dr. Choi has published more than 20 peer reviewed articles and holds a number of patents in the area of polymorphs. He formerly headed the preformulation and solid state characterization functions at Hoffmann-La Roche.